Novel Gallium Imaging in Hepatocellular Carcinoma

Status unconfirmed · Phase 2

Conditions studied: Hepatocellular Carcinoma

In brief

The aim of the present study is to validate the uptake of novel, positron emitting radiotracer, 68Gallium Citrate in hepatocellular carcinoma(HCC). The investigators also aim to evaluate the sensitivity of 68Gallium (68Ga)-citrate positron emission tomography/computed tomography (PET/CT) for the identification of intrahepatic HCC lesions in comparison with existing modalities: computed tomography (CT) alone and magnetic resonance imaging (MRI). The investigators expect that 68Ga-citrate PET/CT will offer a sensitive functional imaging modality for identification of HCC lesions in the liver. The investigators intend to use the results of this preliminary study to fuel further studies in the utility of 68Ga-citrate PET/CT for HCC treatment monitoring.

Key facts

Study ID

NCT03116945

Run by

Rutgers, The State University of New Jersey

People needed

18

Starts

2016-06-01

Expected to finish

2020-12-01

Last updated by the study team

2019-01-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least one biopsy-confirmed or Liver Imaging Reporting and Data System (LI-RADS)- 5 HCC lesion, diagnosed within the past 6 weeks.
• Lesion size greater than or equal to 3cm
• At least one triple-phase CT or MRI of the liver prior to medical or surgical therapy

You may not qualify if…

• Pregnant or breast-feeding women.
• Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study.
• Inability to consent
• Prior medical or surgical therapy for HCC, including chemoembolization, radiofrequency ablation, and lobectomy
• Known or suspected hypersensitivity to metals or gallium

Where it is running

• Rutgers New Jersey Medical School — Newark, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.